Suresh Rana1, Kevin Rogers, Terry Lee, Daniel Reed, Christopher Biggs. 1. Department of Radiation Oncology, Arizona Center for Cancer Care, Peoria, Arizona; Department of Medical Physics, ProCure Proton Therapy Center, Oklahoma City, OK, USA.
Abstract
PURPOSE: The purpose of this study is to assess the dosimetric impact of Acuros XB dose calculation algorithm (AXB), in comparisons with Anisotropic Analytical Algorithm (AAA) calculations in prostate cancer treatment using RapidArc. MATERIALS AND METHODS: A computed tomography (CT) dataset of low-risk prostate cancer patients treated at Arizona Center for Cancer Care was selected and contoured for prostate, seminal vesicles, and organs at risk (OARs)(rectum, bladder, and femur heads). Plans were created for 6 MV photon beam using RapidArc technique in Eclipse treatment planning system. Dose calculations were performed with AAA and AXB for same number of monitor units and identical beam setup. Mean and maximum doses to planning target volume (PTV) and OARs were analyzed. Additionally, minimum dose to PTV and V100 was analyzed. Finally, point-dose difference between planar dose distributions of AAA and AXB plans was investigated. RESULTS: The highest dose difference was up to 0.43% (range: 0.05-0.43%, P> 0.05) for PTV and 1.98% (range: 0.22-1.98%, P> 0.05) for OARs with AAA predicting higher dose than AXB. The V100 values of AAA plans (95 %) and AXB plans (range: 93.1-97.9 %) had an average difference of 0.89 ± 1.47% with no statistical significance (P = 0.25411). The point-dose difference analysis showed that AAA predicted higher dose than AXB at significantly higher percentage (in average 94.15) of total evaluated points. CONCLUSION: The dosimetric results of this study suggest that the AXB can perform the dose computation comparable to AAA in RapidArc prostate cancer treatment plans that are generated by a partial single-arc technique.
PURPOSE: The purpose of this study is to assess the dosimetric impact of Acuros XB dose calculation algorithm (AXB), in comparisons with Anisotropic Analytical Algorithm (AAA) calculations in prostate cancer treatment using RapidArc. MATERIALS AND METHODS: A computed tomography (CT) dataset of low-risk prostate cancerpatients treated at Arizona Center for Cancer Care was selected and contoured for prostate, seminal vesicles, and organs at risk (OARs)(rectum, bladder, and femur heads). Plans were created for 6 MV photon beam using RapidArc technique in Eclipse treatment planning system. Dose calculations were performed with AAA and AXB for same number of monitor units and identical beam setup. Mean and maximum doses to planning target volume (PTV) and OARs were analyzed. Additionally, minimum dose to PTV and V100 was analyzed. Finally, point-dose difference between planar dose distributions of AAA and AXB plans was investigated. RESULTS: The highest dose difference was up to 0.43% (range: 0.05-0.43%, P> 0.05) for PTV and 1.98% (range: 0.22-1.98%, P> 0.05) for OARs with AAA predicting higher dose than AXB. The V100 values of AAA plans (95 %) and AXB plans (range: 93.1-97.9 %) had an average difference of 0.89 ± 1.47% with no statistical significance (P = 0.25411). The point-dose difference analysis showed that AAA predicted higher dose than AXB at significantly higher percentage (in average 94.15) of total evaluated points. CONCLUSION: The dosimetric results of this study suggest that the AXB can perform the dose computation comparable to AAA in RapidArc prostate cancer treatment plans that are generated by a partial single-arc technique.